How did Vericel's revenue and expenses trend in Q4 2024?

Vericel's revenue and expenses in Q4 2024 showed a business-focused trend, with the company's net income standing at $19.81 million. The total operating expenses were $38.61 million, which were primarily attributed to the third-generation autologous chondrocyte implantation product. The revenue by segment for this product was $197.31 million, indicating a strong performance. Additionally, Vericel had a revenue of $128.97 million from the Epicel product and $36.62 million from the Nexobrid product. The company's financial performance in Q4 2024 reflects a solid business strategy with significant revenue generation and effective expense management.

1/3

VCEL Revenue By Business